

Please cancel claims 20, 22-34, 36-49, 60-61, 63-68, and 189.

REMARKS

In response to the Restriction Requirement, Applicants hereby elect Group V, claims 50 and 52-59, for examination at this time. Applicants note that these claims are directed to methods for treating cancer by administering a cell adhesion modulating agent that comprises 3-16 amino acid residues, rather than by administering a tripeptide as indicated in the Restriction Requirement.


In view of the above election, Applicants hereby cancel claims 20, 22-34, 36-49, 60-61, 63-68, and 189 without prejudice to the filing of any divisional, continuation, or continuation-in-part application. Claim 50 has been amended to eliminate the non-elected subject matter without prejudice. Claim 58 has been amended to correct a typographical error. Consideration of the elected claims is now requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version With Markings to Show Changes Made.**" Also Enclosed is a copy of Limited Recognition Under 37 CFR § 10.9(b).

Respectfully submitted,

Orest W. Blaschuk et al.

Seed Intellectual Property Law Group PLLC



Qing Lin, Ph.D.

(See Limited Recognition)

QXL:jab

Enclosures:

- Postcard
- Check
- Form PTO/SB/21
- Form PTO/SB/17 (+ copy)
- Petition for an Extension of Time
- Copy of Limited Recognition Under 37 CFR § 10.9(b)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900 / Fax: (206) 682-6031
D:\NPort\NManage\JUD\B347960_1.DOC

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 20, 22-34, 36-49, 60-61, 63-68, and 189 have been canceled.

Claims 50 and 58 have been amended as follows:

50. (Twice Amended) A method for treating cancer in a mammal, comprising administering to a mammal a cell adhesion modulating agent, wherein said modulating agent comprises

(a) ~~3-16~~ 3-16 amino acid residues, including the sequence His-Ala-Val, or

(b) ~~an antibody or fragment thereof that specifically binds to a cadherin cell adhesion recognition sequence;~~

and wherein said modulating agent inhibits cadherin-mediated cell adhesion.

58. (Amended) A method according to claim 57, wherein said pharmaceutical composition further comprises a modulator of cell adhesion, wherein said modulator comprises a cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin.

**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Qing Lin is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of the Seed Intellectual Property Law Group PLLC. law firm to prepare and prosecute patent applications wherein the patent applicant is the client of the Seed Intellectual Property Law Group PLLC. law firm, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Seed Intellectual Property Law Group PLLC. law firm. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Qing Lin ceases to lawfully remain and reside in the United States, (ii) Qing Lin's employment with the Seed Intellectual Property Law Group PLLC. law firm ceases or is terminated, or (iii) Qing Lin's current Employment Authorization card expires.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: May 17, 2003



Harry I. Moatz
Director of Enrollment and Discipline